Basel, Switzerland – In one of the largest investment announcements in the pharmaceutical industry this year, Swiss healthcare giant Roche revealed plans to invest $50 billion in the United States over the next five years.
The sweeping investment will expand the company’s presence in research, development, and manufacturing across key states, creating more than 12,000 new jobs, including 1,000 positions within Roche and thousands more in related industries.
The announcement was made in a statement from Roche on Monday, with CEO Thomas Schinecker emphasizing the company’s long-standing commitment to the U.S. as a hub for innovation.
“Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US,” said Schinecker. “Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”
Major Expansions and New Sites
The investment spans across Indiana, Pennsylvania, Massachusetts, California, and several other states. Key initiatives include:
A state-of-the-art gene therapy manufacturing facility in Pennsylvania
A new 900,000-square-foot site for manufacturing next-generation weight loss medications (location pending announcement)
A continuous glucose monitoring production plant in Indiana
A new AI-focused R&D center in Massachusetts, which will also serve as a hub for cardiovascular, renal, and metabolic disease research
Expanded R&D and manufacturing sites in Arizona, Indiana, and California
The company also plans to bolster manufacturing and distribution capabilities in Kentucky, New Jersey, Oregon, and California, further building on its current U.S. footprint of 25,000 employees across 24 locations.
A Trade Shift and Economic Impact
According to the company, these investments will shift its trade balance, with Roche expected to export more medicines from the U.S. than it imports once the new infrastructure is operational. The diagnostics division already exports more than it imports from the U.S., and this trend is set to grow with the upcoming expansion.
In total, Roche operates 15 R&D centers and 13 manufacturing sites in the U.S., and the new commitment further cements its role as a major contributor to the American biotech and diagnostics landscape.
“We are proud of our 110-year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions,” Roche said in a statement.
This bold move comes as the biotech sector continues to recover and accelerate in the wake of recent global healthcare challenges, with an emphasis on local manufacturing and rapid technological innovation. Roche’s investments signal not just growth, but a deepening of transatlantic ties in health innovation.
